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Neointimal hyperplasia is a vascular remodeling process involving multiple cell types that is particularly aggressive 
in hypertension and contributes to atherosclerotic coronary artery 
disease.1 Although dysfunction of endothelial cells and abnormal 
growth of vascular smooth muscle cells (SMCs) contributes 
to the cause of neointimal formation,1 c-Kit+ progenitor cells 
originating from both vascular and extravascular (bone marrow) 
sources may also contribute to the pathophysiology of injury-
induced neointimal hyperplasia.2–5 In this context, CD34+/c-Kit+ 
mononuclear cells can differentiate (in response to growth factors 
like platelet derived growth factor, which is released during in-
jury) into cells that express a SMC phenotype and subsequently 
contribute to neointimal formation by migrating to the site of in-
jury and proliferating.6–10 While the relative contribution of pro-
genitor SMCs (P-SMCs) in neointimal formation remains an 
open question, studies conducted in the last decade suggest that 
P-SMCs derived from CD34+/c-Kit+ mononuclear cells con-
tribute to neointimal thickening by 6% to 60%.4,5 Although circu-
lating bone marrow/hematopoietic-derived CD34+/c-Kit+ cells 
are postulated to be the key extravascular source of neointimal 
P-SMCs,2,5 local c-Kit+ cells of vascular adventitial origin may 
also contribute to neointimal formation.2
Importantly, dysfunction and abnormal growth of vascular 
cells involved in neointimal hyperplasia is attenuated by en-
dogenous molecules generated by vascular injury.1 In this re-
gard, adenosine, an endogenous purine nucleoside also known 
as a retaliatory metabolite, is a regulator of cell function that 
is generated in response to cell injury and stress and may pro-
vide vascular protection.11,12 The biological effects of adeno-
sine are mediated via multiple adenosine receptors identified 
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as A1, A2A, A2B, and A3.11,12 Work by us and others show that 
adenosine, via A2B receptors, inhibits SMC growth and bal-
loon injury–induced neointimal formation in rats.13,14
A2B receptors are referred to as the low affinity aden-
osine receptor because the binding affinity of A2B receptors 
for adenosine is lower than that of A1, A2A, and A3 receptors. 
Nonetheless, the functional relevance of A2B receptors is sup-
ported by its link to key intracellular signaling pathways.15 
Moreover, A2B receptors are highly responsive to biological 
processes and mediators, which induce its expression by both 
transcriptional and post-transcription mechanisms.15 For ex-
ample, during hypoxia and inflammation, there is increased 
production of adenosine and augmented expression of A2B 
receptors, in part because adenosine increases A2B receptor 
expression. These responses suggest that A2B receptors may 
play a dynamic pathophysiological role in many diseases.15
There is mounting evidence that the adenosine/A2B receptor 
system plays a particularly important role in vascular diseases. 
For example, A2B-receptor expression is increased following 
vascular injury,14 and knockdown of A2B receptors as well as 
CD73 (an ecto-nucleotidase that converts 5’-AMP to adeno-
sine on cell surfaces) results in vessel wall thickening.16–18 Also, 
treatment with A2B-receptor agonists prevents injury-induced 
neointima formation,14 and CD73-derived adenosine prevents 
cardiac fibrosis and heart failure.18 As reviewed before,13 via 
A2B receptors, adenosine inhibits abnormal growth of mul-
tiple cell types involved in cardiovascular and renal diseases. 
Specifically, activation of A2B receptors inhibits the growth 
of human glomerular mesangial cells (phenotypically similar 
to vascular SMCs), rat preglomerular SMCs, and rat cardiac 
fibroblasts. In addition, and again via A2B receptors, adenosine 
actually stimulates the proliferation of cells that promote vas-
cular health. In this regard, studies show that the adenosine/
A2B-receptor system augments growth of rat aortic,13 rat renal 
microvascular,19 and porcine coronary endothelial cells,13 as 
well as human renal epithelial cells.18 Additionally, adenosine 
has several other desirable tissue-protecting actions such as 
promoting neovascularization20 and preventing and reducing 
inflammation and hypoxia.15 Hence, adenosine per se, adeno-
sine receptor agonists, or adenosine-modulating drugs (ie, the 
broad class of adenosinergic drugs) may be useful for prevent-
ing and treating a number of cardiovascular and renal diseases 
induced by hypertension, particularly those associated with 
excessive proliferation or migration of neointimal cells (in-
cluding SMCs or progenitor SMCs) or immune cells.
As P-SMCs derived from CD34+/c-Kit+ mononuclear 
cells contribute to neointimal formation,4,5 it is conceivable 
that the ability of adenosine to attenuate neointimal hyper-
plasia is mediated in part by adenosine’s effects on P-SMC 
proliferation and migration. In support of this hypothesis, 
adenosine, via A2B receptors, reduces vascular adhesion of 
inflammatory cells,21induces growth of CD34+ derived pro-
genitor endothelial cells, and promotes angiogenesis20–22; how-
ever, whether adenosine influences growth of CD34+/c-Kit+ 
derived P-SMCs remains unknown. Moreover, the impact of 
adenosine on the presence of c-Kit+ cells in injury-induced 
neointimal formation is unknown. As via A2B receptors aden-
osine inhibits SMC growth and induces growth of endothe-
lial and progenitor endothelial cells,13,14,20,22 and A2B receptor 
expression is increased following vascular injury,14 we hy-
pothesize that inhibitory actions of adenosine on CD34+/c-
Kit+ P-SMCs contributes to adenosine’s overall inhibitory 
effects on neointimal formation.
Adenosine inhibits growth of vascular SMCs by down-
regulating mitogen activated Akt-phosphorylation and the sub-
sequent activation of cyclin D1 by inhibiting S-phase kinase 
associated protein-2 (Skp2; promotes the polyubiquitination of 
p27Kip1 and accelerates p27Kip1 degradation)13 and upregulating/
increasing p27kip1, a negative regulator of cell cycle progression. 
Additionally, similar to Wu et al,23 our findings demonstrate 
that the antimitogenic cascade of events driven by adenosine 
in SMCs is triggered by A2B-activated release of cyclic AMP 
(cAMP) and involves PKA (protein kinase A).13 In this context, 
cAMP downregulates the expression of Skp2,23 and thereby 
increases the levels of p27Kip1. In addition, PKA can interfere 
with signaling cascades that phosphorylate (activate) Akt,24 thus 
providing additional mechanisms for inhibiting cyclin D signal-
ing. We hypothesize that similar to SMCs, adenosine inhibits 
growth of CD34+/c-Kit+ derived P-SMCs by engaging the A2B 
receptor/adenylyl cyclase/cAMP/PKA pathway.
The goals of the present study were to investigate: (1) 
whether adenosine inhibits proliferation and migration of 
P-SMCs derived from circulating human CD34+/c-Kit+ mon-
onuclear cells; (2) the underlying receptors and mechanism(s) 
involved; and (3) whether adenosine inhibits the number of 
c-Kit+ cells within the neointima after balloon injury in rats.
Methods
The authors declare that all supporting data are available within the 
article (online-only Data Supplement).
Details of all methods used are available in the online-only Data 
Supplement. It provides information on materials and reagents used 
(Table S1 in the online-only Data Supplement), culture of human 
P-SMCs from peripheral CD34+ mononuclear cells, cell growth 
(3H-thymidine incorporation, 3H-proline incorporation, and cell num-
ber) assays, cell migration, Western blotting for intracellular proteins, 
siRNA mediated A2B-receptor knockdown, cAMP assay, immuno-
magnetic isolation of c-Kit+ cells; carotid artery injury studies, and 
flow cytometry.
Culture of P-SMCs
P-SMCs were cultured from CD34+ mononuclear cells magnetically 
isolated as previously described.25–29 Briefly, peripheral blood (10 mL) 
was collected in heparinized tubes from healthy women (n=13; mean 
age 36±5, nonsmokers). Blood collection to isolate and culture pro-
genitor cells was approved by the institutional ethics commission at 
University Hospital Zurich (stv-Nr 04/2006) and Kantonal etic-com-
mission (KEK) with written consent obtained before blood collection. 
Similarly, the role of adenosine and A2B receptors in regulating P-SMC 
growth was also assessed in P-SMCs cultured from peripheral CD34+ 
cells from healthy male donors (n=3, mean age 27.3±5.4).
Carotid Artery Injury Studies
Balloon catheter-induced carotid artery injury in rats was performed 
as described previously by us13 and conformed to internationally ac-
cepted standards and guidelines set by the animal welfare committee 
and approved by the institutional review board. To assess the impact 
of Cl-Ad on P-SMC infiltration after balloon injury, animals (pla-
cebo n=7, treated n=7) receiving the vehicle or Cl-Ad were sacrificed 
and perfused-fixed 7 days after balloon injury and sections immu-
nostained for c-Kit+ cells to assess their contribution to neo-intimal 
thickening. The sections of the stained carotid arteries were viewed 
and analyzed in a blinded fashion.
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Statistics
Treatment effects on cross-sectional areas were analyzed by using 
ANOVA or the nonparametric Kruskal-Wallis test. Expression and 
growth data was analyzed using ANOVA and statistical significance 
(P<0.05) was calculated using Fisher Least Significant Difference 
test. All growth experiments were performed in triplicates or quadru-
plicates with 3 to 4 separate cultures.
Results
The experiments described below required the use of a large 
number of adenosinergic drugs. To improve readability, here 
we summarize the activity of these pharmacological probes and 
provide abbreviations: 2-Chloroadenosine (Cl-Ad) is a stable 
adenosine analogue and nonselective adenosine receptor ago-
nist; 5’-N-ethylcarboxamidoadenosine is a nonselective aden-
osine receptor agonist; 5’-N-methylcarboxamidoadenosine 
(MECA) is a nonselective adenosine receptor agonist; N6-
cyclopentyladenosine (CPA) is a selective A1 receptor ag-
onist; CGS21680 (CGS) is a selective A2A receptor agonist; 
BAY60-6583 (BAY) is a selective A2B receptor agonist; 
1-Deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-
yl]-N-methyl-β-D-ribofuranuronamide (IB-MECA) is a selec-
tive A3 receptor agonist; 8-Cyclopentyl-1,3-dipropylxanthine 
(DPCPX) is a selective A1 receptor antagonist; SCH442416 
(SCH) is a selective A2A receptor antagonist; MRS1754 (MRS) 
is a selective A2B receptor antagonist; VUF5574 (VUF) is a se-
lective A3 receptor antagonist; Erythro-9-(2-hydroxy-3-nonyl) 
adenine (EHNA) increases endogenous adenosine by inhibit-
ing adenosine deaminase and thus reducing the metabolism 
of adenosine to inosine; 5-iodotubercidin (IDO) increases en-
dogenous adenosine by inhibiting adenosine kinase and thus 
reducing the metabolism of adenosine to 5’-AMP.
As shown in Figure 1A, progenitor cells magnetically 
isolated from mononuclear cells using a CD34 separation 
kit expressed CD34 (green) and c-Kit (orange). As shown in 
Figure S1, soon after plating, CD34+/c-Kit+ cells developed 
a hill-and-valley appearance. Colonies of cells with elongated 
smooth muscle like morphology were selectively isolated, 
characterized, and cultured. P-SMCs had characteristic elon-
gated and spindle shaped morphologically similar to SMCs, 
but not progenitor endothelial cells (Figure S1). After the third 
passage, P-SMCs took on an even more SMC-like morphology 
(elongated and spindle shaped; Figure S1). P-SMCs in third 
passage were further immune-characterized for SMC pheno-
type. As shown in Figure 1B through 1D, P-SMCs showed 
positive immunostaining for alpha smooth muscle actin, 
vimentin, and desmin and were negative for von Willibrand 
factor, an endothelial cell marker. Importantly, Western blot-
ting of P-SMCs lysates revealed expression of PDGFR-B and 
SM22-α (Figure 1E), established markers for P-SMCs.4,5
The expression profile of adenosine receptor subtypes deter-
mines the overall pharmacology and cellular actions of aden-
osine. Hence, we assessed their presence in human P-SMCs. 
As shown in Figure 1F, Western blotting detected strong bands 
for A1 and A2B receptors, a faint band for A2A receptors and no 
signal for A3 receptors. These findings suggest a potential role 
for A2B receptors in mediating adenosine actions in P-SMCs.
Treatment of P-SMCs with Cl-Ad (0.01–1 µmol/L; stable 
adenosine analogue) for 4 days concentration-dependently 
attenuated cell proliferation (Figure 2A). Using various 
pharmacological agents (adenosine receptor subtype selective 
and nonselective agonists and antagonists), we further assessed 
the role of all adenosine receptor subtypes (A1, A2A, A2B, and 
A3) in mediating the antimitogenic effects of adenosine in 
P-SMCs. The highest (1 μmol/L) concentrations of CPA (A1-
receptor selective agonist), CGS (A2A-receptor selective ago-
nist), and IB-MECA (A3-receptor selective agonist) failed to 
inhibit cell proliferation (Figure 2A). MECA was more potent 
than 5’-N-ethylcarboxamidoadenosine (both are nonselective 
adenosine receptor agonists; Figure 2A). MRS (A2B-receptor 
selective antagonist), but not DPCPX (A1-receptor selective 
antagonist), SCH (A2A-receptor selective antagonist) or VUF 
(A3-receptor selective antagonist), blocked the inhibitor effects 
of Cl-Ad on 3H-thymidine incorporation, an index of DNA syn-
thesis (all antagonists at 100 nmol/L; Figure 2B). Moreover, 
the inhibitory effects of Cl-Ad on cell number and 3H-proline 
Figure 1. A, Depicts expression of CD34 (green) and c-Kit (orange) in 
magnetically separated CD34+ mononuclear cells obtained from human 
blood. Soon after plating, CD34+/c-Kit+ cells developed a hill-and-
valley appearance. Colonies of cells with elongated smooth muscle–like 
morphology were selectively isolated, characterized, and cultured. 
Progenitor smooth muscle cells (P-SMCs) had characteristic elongated 
and spindle shaped morphologically similar to SMCs, but not progenitor 
endothelial cells. After the third passage, P-SMCs took on an even more 
SMC-like morphology (elongated and spindle shaped; Figure S1). P-SMCs 
in third passage showed positive immunostaining for alpha smooth muscle 
actin (B), vimentin (C), and desmin (D) and were negative for von Willibrand 
factor, an endothelial cell marker. Western blotting of P-SMC lysates 
revealed expression of platelet derived growth factor receptor-B and 
SM22-α (E), established markers for P-SMCs. Western blotting detected 
strong bands for A1 and A2B receptors, a faint band for A2A receptors and 
no signal for A3 receptors (F). Molecular weight numbers in blots are in 
kilodaltons (Kda or Kds).
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incorporation (index of collagen synthesis) were reversed by 
MRS, but not by DPCPX, SCH, or VUF (Figure 2B).
Treatment with Cl-Ad and MECA (nonselective aden-
osine receptor agonist), but not CPA (selective A1 agonist), 
CGS (selective A2A agonist), or IB-MECA (selective A3 ag-
onist), inhibited P-SMC migration (Figure 2C, top) and the 
inhibitory effects of Cl-Ad and MECA on cell migration were 
blocked by MRS (Figure 2C, bottom). Neither DPCPX, SCH, 
nor VUF affected the inhibitory actions of Cl-Ad on P-SMC 
migration (Figure 2C, bottom).
To assess whether endogenous adenosine has inhibitory 
effects on P-SMCs, cells were treated with EHNA (blocks aden-
osine deaminase), IDO (blocks adenosine kinase) or both to in-
crease endogenous adenosine. Treatment with EHNA as well 
as IDO inhibited P-SMC mitogenesis and these effects were 
enhanced in cells treated with EHNA plus IDO (Figure 2D, 
upper). The antimitogenic effects of EHNA plus IDO on P-SMC 
were abrogated by MRS, but not by DPCPX, SCH or VUF 
(Figure 2D, upper). The inhibitory effects of Cl-Ad on P-SMC 
migration were mimicked by endogenous adenosine induced 
by treatment with EHNA plus IDO in P-SMCs (Figure 2D, 
lower). The inhibitory actions of EHNA plus IDO on P-SMC 
migration were abrogated by the A2B antagonist MRS, but not 
by DPCPX, SCH or VUF (Figure 2D, lower). Trypan blue ex-
clusion tests demonstrated that none of the aforementioned 
treatments altered cell viability. These findings indicate that in 
human P-SMCs, A2B receptors dominate the pharmacology of 
adenosine leading to inhibition of cell proliferation, DNA syn-
thesis, collagen synthesis, and cell migration.
We have previously shown that active crosstalk between 
Akt-phosphorylation, Skp2, p27Kip1, and cyclin D1 plays a 
key role in mediating the growth inhibitory effects of aden-
osine in human coronary artery SMCs.13 In the present study 
(Figure 3), treatment of human P-SMCs with Cl-Ad, as well as 
MECA, inhibited Akt phosphorylation and decreased expres-
sion of Skp2 (F-box protein of SCF-Skp2 ubiquitin ligase re-
sponsible for polyubiquitination of and subsequent proteolysis 
of p27Kip1) and upregulated levels of p27Kip1 (p27Kip1 is a neg-
ative regulator of cell cycle progression which blocks cyclin 
action). This effect was to paralleled by inhibition of cyclin 
D1 expression (Figure 3). Moreover, the modulatory effects of 
Cl-Ad and MECA on Akt phosphorylation, Skp2, p27Kip1, and 
Figure 2. Left: (A) depicts concentration-response relationships for the inhibition of cell number by Cl-Ad, N-methylcarboxamidoadenosine (MECA), IB-MECA, 
N-ethylcarboxamidoadenosine (NECA), N6-cyclopentyladenosine (CPA), and CGS21680 in progenitor smooth muscle cells (P-SMCs). B, Depicts the effects 
of Cl-Ad (1 μmol/L) on 3H-thymidine incorporation (top; DNA synthesis), cell number (middle), and 3H-proline incorporation (panel; collagen production) in the 
presence and absence of DPCPX, SCH442416, VUF5574 , and MRS1754 (100 nmol/L) in P-SMCs. *P<0.05 vs no treatment; §Significant reversal of inhibitory 
effects. Values represent mean±SEM from 3 to 4 separate experiments, each conducted in triplicate. Right: upper of (C) depicts the effects of Cl-Ad, MECA, 
CPA, CGS, and IB-MECA (1 μmol/L) on human P-SMC migration. The inhibitory effects of Cl-Ad were mimicked by MECA, but not by CPA, CGS, or IB-MECA. 
Lower of (C) shows that the inhibitory effects of Cl-Ad on P-SMC migration were reversed by MRS, but not by DPCPX, SCH, or VUF. Also, the effects of MECA 
on migration of human P-SMCs were blocked by MRS. Upper (D) show that EHNA (5 µmol/L), IDO (0.1 µmol/L), and EHNA plus IDO inhibited DNA synthesis 
(3H-thymidine incorporation) by human P-SMCs and lower (D) shows that EHNA plus IDO inhibited migration. The inhibitory effects of EHNA and IDO on DNA 
synthesis were significantly enhanced when the adenosine catabolism inhibitors EHNA and IDO were combined. Moreover, the effects of EHNA+IDO were 
reversed by MRS, but not by SCH, DPCPX or VUF, suggesting that endogenous adenosine inhibits P-SMC growth and migration via A2B receptors. *P<0.05 vs 
control; §Significant reversal of the inhibitory effects. Values represent mean±SEM from 3 to 4 separate experiments, each conducted in triplicate.
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cyclin D1 were blocked by MRS (Figure 3), implying a role 
for A2B receptors in mediating the inhibitory effects of adeno-
sine on cell cycle progression in human P-SMCs.
To further assess the role of A2B receptors in P-SMCs, we 
used siRNA to knockdown the expression of A2B receptors 
(Figure 4A). At the functional level, Cl-Ad increased cAMP 
production in P-SMCs (Figure 4B). As stimulation of A2B 
adenosine receptors are known to induce cAMP in SMCs, we 
assessed the effects of A2B receptor knockdown with siRNA 
on Cl-Ad-induced cAMP in P-SMCs. Downregulation of A2B 
receptors in P-SMCs by siRNA (Figure 4B) blocked Cl-Ad 
induced cAMP production; whereas, treatment with nonac-
tive control siRNA had no effect (Figure 4B). Downregulation 
of A2B receptors by siRNA abrogated the inhibitory effects 
of Cl-Ad, MECA, and EHNA plus IDO, but not 8-bromo-
cAMP, on DNA synthesis (Figure 4C). These results further 
support the conclusion that A2B receptors mediate the antimi-
togenic effects of adenosine. We further elucidated the role 
of adenylyl cyclase and protein kinase A in mediating the in-
hibitory effects of Cl-Ad on P-SMC mitogenesis. Treatment 
of P-SMCs with Cl-Ad inhibited mitogenesis in the absence 
(Figure 4D), but not in the presence (Figure 4D), of the adeny-
lyl cyclase inhibitor myristoylated trifluoroacetate or the pro-
tein kinase A inhibitor 2’,5’-dideoxyadenosine.
To assess whether sex influences the inhibitory actions of 
adenosine on P-SMC growth, we conducted experiments in 
P-SMCs cultured from peripheral CD34+ cells obtained from 
males. P-SMCs from males expressed A2B receptors and treat-
ment with Cl-Ad, MECA and BAY (selective A2B receptor 
agonist), but not CGS, CPA or IB-MECA, inhibited P-SMC pro-
liferation (Figure 5A). The concentration-dependent inhibitory 
effects of BAY were of similar magnitude in female and male 
P-SMCs (Figure 5B) and were blocked by MRS. Both Cl-Ad 
and BAY inhibited migration of (Figure 5C) and DNA synthesis 
by (Figure 5D) male P-SMCs. Similar effects were observed 
in male P-SMCs treated with EHNA+IDO to induce endoge-
nous adenosine (Figure 5C and 5D). Moreover, the inhibitory 
effects of Cl-Ad, BAY, and EHNA plus IDO on P-SMC migra-
tion and DNA synthesis were reversed by MRS. Stimulation of 
A2B adenosine receptors with Cl-Ad as well as BAY induced 
cAMP in male P-SMCs and these actions were blocked by 
MRS (Figure 5D). Moreover, BAY inhibited mitogenesis in the 
absence (Figure 5D), but not in the presence (Figure 5D), of the 
adenylyl cyclase inhibitor myristoylated trifluoroacetate or the 
protein kinase A inhibitor 2’,5’-dideoxyadenosine.
Analysis of carotid arteries after morphometric evalua-
tion showed significant intimal thickening after balloon injury, 
and this was abrogated in rats treated with Cl-Ad for 7 days 
(Figure 6A). Compared with the placebo group (n=7; intima 
35,256±9680 pixels), the neointima formation was reduced by 
≈64.5% in rats receiving periarterial Cl-Ad (n=7; 12517±4822 
pixels; P<0.05 versus placebo). Also, the intimal/medial ratio 
was significantly reduced from 1.4±0.02 in placebo group 
to 0.53±0.55 in animals receiving Cl-Ad (Figure 6A). In ca-
rotid arteries obtained from animals receiving placebo, c-Kit+ 
cells were observed in neo-intimal areas (≈16% of total cells; 
Figure 6B). As compared with the placebo group, a significant 
decrease in c-Kit+ cells was observed in arteries obtained from 
animals treated with Cl-Ad (Figure 6B). Moreover, c-Kit+ cells 
were also present in the adventitial areas (Figure 6C). To assess 
whether treatment with Cl-Ad modulates bone marrow–derived 
c-Kit+ cells, we also performed fluorescence-activated cell sort-
ing analysis in marrow-derived mononuclear cells. As shown in 
Figure 6D, treatment with Cl-Ad did not significantly modulate 
the number of CD34+ and c-Kit+ marrow cells. Moreover, aden-
osine A2B receptors were expressed in lysates of c-Kit+ cells iso-
lated by immune-magnetic separation from rat aortas and bone 
marrow (Figure 6E). Treatment with Cl-Ad was not associated 
with any toxic adverse effects, as we have previously shown.13
Discussion
Here, we report the novel finding that adenosine, via A2B 
receptors, attenuates P-SMC proliferation and migration. 
The importance of this discovery is underscored by the fact 
that circulating marrow-derived progenitor cells contribute to 
injury-induced vascular remodeling.4,5 In particular, CD34+/c-
Kit+ progenitor cells acquire a SMC phenotype and thereby 
contribute to injury-induced neointimal thickening.2,4,5 Thus, 
Figure 3. Figure depicts Western blots 
showing the effects of Cl-Ad (0.5 μmol/L), 
Cl-Ad plus MRS1754 (100 nmol/L), 
N-methylcarboxamidoadenosine (MECA; 0.5 
μmol/L), and MECA plus MRS1754 on levels of 
phosphorylated Akt (Akt-P), total Akt, cyclin D1, 
p27Kip1 (p27), and Skp2 expression in human 
progenitor smooth muscle cells (P-SMCs). 
Subconfluent monolayers of P-SMCs were 
growth arrested for 36 h in 0.4% BSA and were 
treated and stimulated with 2.5% FBS for 48 
h. Cell lysates were subsequently analyzed 
by Western blotting. Bar graphs depict the 
optical density ratio, normalized to appropriate 
controls, for the Western blots. *P<0.05 vs 
control; §Significant reversal of the inhibitory 
effects. The experiments were repeated 3× with 
separate cultures.
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agents that inhibit the infiltration and proliferation of CD34+/
c-Kit+ derived SMCs in the vasculature may protect against 
cardiovascular disease.
Our experiments demonstrate that both exogenous and en-
dogenous adenosine inhibited the mitogen-induced activity 
of P-SMCs derived from human CD34+/c-Kit+ mononuclear 
cells. In support of this conclusion, we observed that treat-
ment of P-SMCs either with a metabolically stable adenosine 
analog (Cl-Ad) or with agents that increase endogenous aden-
osine inhibited P-SMC DNA synthesis, cell proliferation, 
collagen synthesis, and cell migration. Importantly, Cl-Ad 
significantly decreased the presence of c-Kit+ cells within the 
neointima after balloon injury.
Our results also support the conclusion that adenosine 
inhibits proliferation and migration of P-SMCs via activation 
of A2B receptors. CPA, CGS, and IB-MECA are selective A1-
receptor, A2A-receptor, and A3-receptor agonists, respectively; 
and DPCPX, SCH and VUF are selective A1-receptor, A2A-
receptor, and A3-receptor antagonists, respectively. As neither 
CPA, CGS, nor IB-MECA inhibited P-SMC proliferation or 
migration and neither DPCPX, SCH nor VUF blocked the in-
hibitory effects of Cl-Ad on P-SMC proliferation or migration, 
it is highly unlikely that A1, A2A, or A3 receptors mediate the 
antimitogenic or antimigratory effects of adenosine on human 
P-SMCs. On the contrary, BAY, a specific A2B-receptor ago-
nist, inhibited P-SMC growth. The facts that BAY and MECA 
mimicked the effects of Cl-Ad on P-SMC proliferation and mi-
gration and the observation that MRS, a specific A2B receptor 
antagonist, attenuated the inhibitory effects of Cl-Ad, BAY, and 
MECA on P-SMCs corroborate the conclusion that A2B recep-
tors mediate the inhibitory effects of adenosine on P-SMC pro-
liferation. This conclusion is further supported by our findings 
that the inhibitory effects of MECA and Cl-Ad on P-SMC pro-
liferation were blocked by siRNA against A2B receptors.
Multiple promitogenic pathways, including Akt, promote 
mitogen-induced proliferative responses at sites of vascular 
dysfunction, damage, or injury. These early signaling path-
ways trigger proliferation of cells, including SMCs, by upregu-
lating progrowth cell cycle regulatory proteins, such as cyclin 
D, and downregulating negative cell cycle regulatory proteins, 
such as p27Kip1, that retard cell-cycle progression.13,23,24 The 
present study showed that treatment with Cl-Ad or MECA in-
hibited phosphorylation of Akt, decreased expression of Skp2, 
increased levels of p27Kip1, and decreased expression of cy-
clin D1. These results are entirely consistent with our obser-
vations in SMCs13 and support this mechanism of action for 
adenosine’s antiproliferative effects in P-SMCs. The role of 
A2B receptors in modulating these key signaling mechanisms 
to negatively influence cell proliferation is further supported by 
our observation that the effects of Cl-Ad and MECA on these 
signaling pathways were blocked by the A2B receptor antago-
nist MRS and by silencing of A2B receptors using siRNA.
Our results demonstrate that treatment with Cl-Ad reduces 
Skp2 expression and this is accompanied by a simultaneous in-
crease in p27Kip1 levels. Additionally, using pharmacological 
agonists and antagonists, we show that the modulatory effects of 
adenosine on Skp2 and p27Kip1 are A2B-receptor mediated. Skp2 
is an F-box protein of SCFSkp2 ubiquitin ligase and therefore 
promotes polyubiquitination of and subsequent proteolysis of 
p27Kip1.23,24,30,31 Because p27Kip1 binds to and inhibits the function 
of cyclin-Cdk complexes (such as cyclin D/Cdk4/6), an increase 
in p27Kip1 levels would inhibit the function of cyclin D. Consistent 
with this mechanism, the present study supports the conclusion 
that via A2B receptors adenosine inhibits P-SMC proliferation in 
part by downregulating Skp2 and upregulating p27Kip1.
Our studies are consistent with the concept that the prox-
imal signaling mechanism by which A2B receptors inhibit 
Figure 4. A, Shows a Western Blot depicting the downregulation of A2B 
receptor expression in human progenitor smooth muscle cells (P-SMCs) 
by siRNA against A2B receptors (no treatment with siRNA [Con]; treated 
with negative-control siRNA [si-Con]; treated with siRNA against A2B 
receptor [siRNA]). B, Depicts the effects of siRNA against A2B receptors 
on the stimulatory effects of Cl-Ad (1 µmol/L) on cAMP levels in P-SMCs 
(no treatment with siRNA [Control]; treated with negative-control siRNA 
[siControl]; treated with siRNA against A2B receptor [siRNA]). C, Depicts 
inhibitory effects of Cl-Ad (Cl-Ad; 1 µmol/L), MECA (1 µmol/L), 8-bromo-
cyclic AMP (cAMP; 10 µmol/L), and Erythro-9-(2-hydroxy-3-nonyl) adenine 
(EHNA; 10 μmol/L) plus 5-iodotubercidin (0.1 µmol/L) on DNA synthesis in 
the absence and presence of A2B receptor siRNA in P-SMCs (no treatment 
with agonists [Con]; treated with negative-control siRNA [siControl]; 
treated with siRNA against A2B receptors [A2B-siRNA]). In (D), bar graphs 
depict DNA synthesis in P-SMCs treated (+Cl-Ad) or not (-Cl-Ad) with Cl-
Ad (0.5 µmol/L) in the presence or absence of a protein kinase A inhibitor 
(myristoylated trifluoroacetate, frag 14-22; 10 µmol/L; PKA-I) or adenylyl 
cyclase inhibitor (2’,5’-dideoxyadenosine; 1 µmol/L; AC-I) for 36 h. Both 
PKA-I and AC-I reversed the inhibitory effects of Cl-Ad on DNA synthesis 
in P-SMCs. *P<0.05 vs no agonist. Values represent mean±SEM from 3 
separate experiments, each conducted in quadruplicates.
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proliferation involves the adenylyl cyclase/cAMP/PKA axis. 
A2B receptors induce cAMP formation via activation of adeny-
lyl cyclase.13 Therefore, cAMP may be involved in mediating 
the effects of Cl-Ad on Akt and Skp2. Our findings that the in-
hibitory effects of Cl-Ad on P-SMC proliferation were signifi-
cantly abrogated by inhibition of adenylyl cyclase and PKA are 
consistent with the hypothesis that A2B-mediated cAMP pro-
duction participates in the antimitogenic effects of Cl-Ad. We 
also observed that in P-SMCs with siRNA-silenced A2B recep-
tors, Cl-Ad-induced cAMP production was abrogated and the 
antimitogenic effects of Cl-Ad and MECA, but not 8-bromo-
cAMP, were prevented. Taken together, these data suggest that 
the antiproliferative effects of Cl-Ad are mediated by cAMP 
produced via stimulation of A2B receptors coupled to adenylyl 
cyclase, followed by cAMP-induced activation of PKA. This 
notion is supported by a previous report that cAMP inhibits 
neointima formation via PKA activation and by downregulat-
ing Skp2 and upregulating p27Kip1 in rat aortic SMCs.23,30–32
Recent studies provide strong evidence for a major role 
of p27Kip1 upregulation in mediating antimitogenic actions.23,30 
Decreased or defective expression of p27Kip1 is linked to 
proliferative disorders including atherosclerosis, restenosis 
after balloon injury and cancer. In animal models, molecular 
approaches for targeted upregulation of p27Kip1 prevent injury-
induced intimal thickening.31 Our finding that Cl-Ad induced 
p27Kip1 expression in P-SMCs via A2B receptors suggests that 
p27Kip1 mediates in part the antimitogenic effects of Cl-Ad. 
Consistent with this notion, our experiments show that the 
stimulatory effects of Cl-Ad on p27Kip1 expression and its in-
hibitory effects on P-SMC proliferation are blocked by A2B 
receptor antagonism or knockdown of A2B receptors.
Using the balloon vascular-injury model, we have pre-
viously shown that Cl-Ad inhibits neointimal formation.13 
Moreover, we demonstrated that treatment with Cl-Ad 
inhibits proliferating cells within the neointima. In the pre-
sent study, Cl-Ad inhibited infiltration of c-Kit+ P-SMCs. 
Moreover, via A2B receptors Cl-Ad inhibited P-SMC growth 
by downregulating Akt phosphorylation, Skp2 expression and 
cyclin D1 expression and upregulating p27kip1 expression, a 
profile which was also observed by us in the neointimal tissue 
after injury in the same model.13 Taken together, these find-
ings suggest that Cl-Ad prevents intimal thickening in part 
by down-regulating the expression of Skp2 and upregulat-
ing p27Kip1 levels. These findings are consistent with reports 
that injury-induced intimal thickening16 and high-lipid-diet-
induced atherosclerosis33 are increased in mice lacking A2B 
receptors, suggesting that the antivasoocclusive effects of 
adenosine are A2B-receptor mediated.
Our findings that application of Cl-Ad peri-arterially 
inhibits injury-induced neointimal thickening has potential 
therapeutic significance. Restenosis is a major and frequent 
complication after balloon-angioplasty for the treatment of 
occlusive coronary artery disease. As increased presence of 
c-Kit+ cells4,5 and abnormal growth of SMCs in neointima 
occurs mainly during the first 7 days post-angioplasty, and 
since peri-arterial application of Cl-Ad inhibits intimal thick-
ening (likely via A2B receptors), application of an A2B-receptor 
agonist to the disease segment of the coronary artery at the 
time of angioplasty may prevent restenosis after balloon angi-
oplasty in humans. Peri-arterial application may also resolve 
the limitations associated with the rapid clearance, short half-
life, or adverse systemic effects of adenosine or its analogs.
Figure 5. A, Depicts the expression 
of A2B adenosine receptors and the 
inhibition of cell number by Cl-Ad, 
N-methylcarboxamidoadenosine (MECA), 
IB-MECA, N-ethylcarboxamidoadenosine 
(NECA), N6-cyclopentyladenosine (CPA), BAY, 
and CGS (100 nmol/L) in male progenitor 
smooth muscle cells (P-SMCs) cultures. B, 
Shows concentration-response relationships 
for the inhibition of cell number by BAY in 
male and female P-SMCs, and the reversal of 
their inhibitory effects by MRS (100 nmol/L). 
C, Summarizes the inhibitory effects of Cl-Ad, 
BAY, and EHNA (5 µmol/L) plus IDO (0.1 µmol/) 
on male P-SMC migration in the presence and 
absence of MRS. Top (D) depicts inhibitory 
effects of of Cl-Ad, BAY, and EHNA plus IDO 
on DNA synthesis in the presence and absence 
of MRS in male P-SMCs; middle (D) depicts 
the stimulatory effects of Cl-Ad and BAY on 
cAMP levels in male P-SMCs in the presence 
and absence of MRS; bottom (D) depicts DNA 
synthesis in male P-SMCs treated (+BAY) or not 
(−BAY) with BAY (0.5 µmol/L) in the presence 
or absence of a PKA (protein kinase A) inhibitor 
(myristoylated trifluoroacetate, frag 14-22; 10 
µmol/L; PKA-I) or adenylyl cyclase inhibitor 
(2’,5’-dideoxyadenosine; 1 µmol/L; AC-I) for 36 
h. Both PKA-I and AC-I reversed the inhibitory 
effects of BAY on DNA synthesis in male 
P-SMCs. *P<0.05 vs no agonist; §Significant 
reversal of effects. Values represent mean±SEM 
from 3 separate experiments, each conducted 
in triplicates.
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Our findings demonstrate that peri-arterial application of 
Cl-Ad significantly decreases the number of c-Kit+ cells within 
the neointima; however, the source of these cells remains un-
clear. It is well established that marrow-derived c-Kit+ mono-
nuclear cells contribute to neointimal thickening2–5; however, 
c-Kit+ cells have also been shown to be present within the 
vascular adventitia2 and can contribute to the vascular remod-
eling process by migrating into the intima after injury.2–4 The 
decrease in neointimal cells in response to Cl-Ad was not due 
to decreased production of marrow c-Kit+ or CD34 +cells, as 
Cl-Ad treatment did not lower their numbers. We found, how-
ever, that c-Kit+ cells were also present in the vascular adven-
titia. Hence, it is possible that both circulating and adventitial 
c-Kit+ cells can migrate to the site of injury and contribute to 
neointimal formation. This contention is supported by our find-
ing that Cl-Ad inhibits P-SMC migration. It has been argued 
that the early accumulation of c-Kit+ cells in the luminal as-
pect of injured vessels is most likely derived from the circu-
lation/marrow; however, concrete evidence remains elusive.4,5
The contribution of c-Kit+ cells in neointimal formation var-
ies from 6% to 60%.4,5 In the present study, the number of c-Kit+ 
cells, 7 days post-surgery, was ≈8%. As cells can lose expres-
sion of c-Kit+ with time, their true numbers within the neointima 
may be underestimated.1,4 We have previously shown that Cl-Ad 
significantly inhibits the number of proliferating SMC-like 
cells in the neointima.13 As similar to SMCs, adenosine inhibits 
growth of CD34+/c-Kit+ derived P-SMCs, it is likely that aden-
osine blocks proliferation of both SMCs and P-SMCs. However, 
due to lack of true/concrete specific markers, it is hard to differ-
entiate between proliferating SMCs and P-SMCs.
Our finding show that A2B-receptor activation inhibits in 
vitro growth of c-Kit-derived P-SMCs obtained from both 
females and males. This strongly suggests that A2B-receptor 
agonists would counteract the vascular remodeling process as-
sociated with occlusive disorders in a sex-independent fashion. 
Nonetheless, as sex differences in adenosine responses are 
known to occur,34 in vivo experiments are required to confirm 
our in vitro findings of sex independence.
Previous studies show that via A2B receptors adenosine 
induces growth of CD34+-derived progenitor endothelial 
cells and drives them to initiate recovery at sites of endo-
thelial injury19,22 and that A2B receptors are necessary for the 
early angiogenic process. These findings suggest that aden-
osine may protect against vascular remodeling by driving 
the relevant progenitors to repair the damaged endothelium 
(induce CD34+ progenitor endothelial cells) and by inhibit-
ing P-SMCs that contribute to neointimal formation. Thus, it 
would be interesting to know if in injured/denuded vessels, 
application of Cl-Ad increases endothelial cell number and 
promotes endothelial recovery. Notably, A2B receptors me-
diate anti-inflammatory actions and inhibit vascular adhesion 
of macrophages21; moreover, CD34+ hematopoietic cells can 
develop into both progenitor endothelial cells and SMCs.2 As 
all of these cell types are represented within the developing 
neointima, we hypothesize that A2B receptors prevent injury-
induced neointimal formation by: (1) inhibiting proliferation 
and migration of vascular SMCs and CD34+/c-Kit+ derived 
P-SMCs; (2) inducing endothelial repair by activating growth, 
adhesion and angiogenesis of endothelial cells as well as 
CD34+ derived progenitor endothelial cells; and (3) inhibiting 
adhesion of pro-inflammatory monocytes/macrophages.
Based on our observations, the adenosine/A2B-receptor 
system may protect against injury-induced vessel wall thick-
ening; however, there are caveats. Overproduction of adenosine 
Figure 6. A, Shows the inhibitory effects 
of Cl-Ad (20 μmol/L in 25% pluronic gel) on 
intimal thickening after balloon injury. Image 
shows representative photomicrographs (10× 
magnification) of the cross-sections of rat 
carotid arteries 7 days after balloon injury in 
vehicle (Veh) vs Cl-Ad-treated rats. Bar graph 
compares the intima-to-media ratio after 
injury in rats receiving vehicle (n=7) vs Cl-Ad. 
Data are mean±SEM; * indicates P<0.05 vs 
vehicle. B, Depicts inhibitory effects of Cl-Ad 
on infiltration and presence of c-Kit positive 
cells within the intima 7 days after balloon injury 
(brownish-red staining using c-Kit antibodies). 
Image shows representative photomicrographs 
(40× magnification) of cross sections of 
carotid arteries stained for c-Kit. Bar graph 
compares the number of c-Kit positive cells 
in vehicle vs Cl-Ad treated groups. Data are 
mean±SEM; * indicates P<0.05 vs vehicle. C, 
Shows representative photomicrograph (100× 
magnification) depicting the presence of c-Kit 
positive cells within the vascular adventitia 
7 days after balloon injury. In (D), the bar 
graph shows no difference in the number of 
marrow-derived CD34+ and c-Kit+ cells from 
rats treated with vehicle or Cl-Ad. E, Depicts 
Western blots demonstrating the presence 
of A2B receptors on SMCs and c-Kit+ cells 
magnetically separated from enzymatically 
dispersed cells from rat aortas (A-cKit cells; 
n=7) and from bone marrow cells (M-cKit cells; 
n=7) using c-Kit antibodies.
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and expression of A2B receptors has been shown to induce del-
eterious actions and to be associated with the pathophysiology 
of lung fibrosis, chronic obstructive pulmonary disease, chronic 
renal disease and renal fibrosis, diabetes mellitus, cancer, wound 
healing, inflammatory conditions, autoimmune disease, cere-
bral ischemia and neurodegenerative disease, preeclampsia, 
and sickle cell disease.35,36 As adenosine receptors, including 
the A2B-receptor, can be desensitized by their ligand,37 it is fea-
sible that excessive adenosine production may have a negative 
impact on its receptor-mediated actions. Also, the time frame of 
A2B-receptor activation may be critical, with short-term exposure 
providing beneficial vascular effects and long-term exposure 
promoting pro-fibrotic actions. From the therapeutic perspective, 
several adenosine receptor agonists and antagonists, as well as 
adenosine synthesis inhibitors, are under development for clinical 
use.38,39 A2B agonists are being developed to target cardiovascular 
disease14; whereas, A2B antagonists and CD73 inhibitors are being 
developed to target angiogenesis in cancer/tumors,40,41 renal fi-
brosis, pulmonary fibrosis associated with chronic obstructive 
pulmonary disease, pulmonary hypertension, and dermal fibrosis. 
As adenosine can have both beneficial and deleterious effects, the 
challenge going forward is to design drugs that maximize effi-
cacy and minimize deleterious side effects.
In conclusion and as summarized in the graphical abstract, 
we provide strong evidence that: (1) adenosine inhibits neointi-
mal formation and the infiltration of c-Kit+ cells; (2) adenosine 
inhibits proliferation and migration of human P-SMCs de-
rived from CD34+/c-Kit+ mononuclear cells; (3) the inhibitory 
effects of adenosine on P-SMC proliferation are mediated via 
A2B-receptor activation of adenylyl cyclase leading to the accu-
mulation of cAMP; (4) adenosine inhibits P-SMC proliferation 
by activating PKA and blocking multiple pro-growth signaling 
pathways (Akt, Skp2, cyclin D1) and upregulating p27kip1, a 
negative regulator of cell cycle progression; and (5) activation 
of A2B receptors may prevent vascular remodeling associated 
with coronary artery disease, hypertension, atherosclerosis and 
restenosis.
Perspectives
We demonstrate that adenosine inhibits neointimal formation 
and P-SMC growth via A2B receptors. Because infiltration and 
abnormal growth of P-SMCs importantly contributes to the vas-
cular remodeling process associated with vaso-occlusive disor-
ders, our results suggest that abnormal and decreased expression 
of A2B receptors or decreased synthesis of adenosine may con-
tribute to the abnormal growth of P-SMCs in various vaso-occlu-
sive pathologies. Development of molecular approaches and 
pharmacological agents that activate and increase A2B receptors 
may be of therapeutic importance in protecting against vascular 
remodeling associated with coronary artery disease, hyperten-
sion, atherosclerosis, and restenosis after balloon angioplasty.
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What Is New?
•	Endogenous and exogenous adenosine inhibit the proliferation and mi-
gration of human progenitor smooth muscle cells derived from CD34+/c-
Kit+ circulating mononuclear cells.
•	The inhibitory effect of adenosine on human progenitor smooth muscle 
cells is mediated via A
2B
-receptor activation of adenylyl cyclase leading 
to the accumulation of cAMP and stimulation of PKA (protein kinase A).
•	PKA inhibits human coronary progenitor smooth muscle cell prolifera-
tion by downregulating Akt-phosphorylation, Skp2, and cyclin D1 and by 
upregulating p27kip1.
•	Peri-arterial application of adenosine analogues in a slow release gel 
formulation inhibits the accumulation of c-Kit+ cells and attenuates vas-
cular injury-induced neointimal hyperplasia.
What Is Relevant?
•	A2B receptor activation is a straightforward approach to inhibit both vas-
cular and progenitor SMC proliferation and migration.
•	Peri-arterial application of A2B-receptor agonists may be of therapeutic 
importance in inhibiting neointimal hyperplasia while obviating unwanted 
systemic adverse effects.
•	Adenosine and its A2B specific analogs can abrogate neointimal progres-
sion by blocking growth of local and extravascular SMCs (adult and pro-
genitor SMCs), which contribute to neointimal thickening.
•	Other agents that modulate the actions of Akt, Skp2, p27Kip1, and cyclin 
D may have therapeutic efficacy in cardiovascular medicine.
Summary
The adenosine/A
2B
 receptor/cAMP/protein kinase A axis inhibits 
human coronary progenitor smooth muscle cell proliferation and 
migration by blocking multiple pro-growth signaling pathways 
(Akt-phosdphorylation, Skp2, cyclin D1) and upregulating p27kip1, 
a negative regulator of cell cycle progression.
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